(ZLAB) Zai Lab - Ratings and Ratios
Zejula,Vyvgart,NUZYRA,Optune,Qinlock,Xacduro,Augtyro
ZLAB EPS (Earnings per Share)
ZLAB Revenue
Description: ZLAB Zai Lab
Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company focused on developing and commercializing treatments for various medical conditions, including oncology, immunology, neuroscience, and infectious diseases. The company has a diverse portfolio of commercial products, including Zejula, VYVGART, NUZYRA, Optune, Qinlock, Xacduro, and Augtyro, which address a range of serious health conditions.
From a business perspective, Zai Lab has established multiple strategic partnerships with prominent pharmaceutical companies, such as Tesaro, NovoCure, Deciphera Pharmaceuticals, Paratek Bermuda, argenx BV, Bristol-Myers Squibb, Amgen, Innoviva, Karuna Therapeutics, and Pfizer. These collaborations enable the company to leverage its partners expertise and resources to develop and commercialize its products, enhancing its pipeline and revenue potential.
To evaluate Zai Labs performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and pipeline development progress are crucial. The companys revenue growth can be assessed by analyzing its quarterly and annual sales data. Additionally, the adoption rates of its commercial products, such as Zejula and VYVGART, can indicate the companys ability to penetrate the market and compete with existing treatments. Furthermore, the progress of its pipeline development, including the advancement of bemarituzumab, tisotumab vedotin, and repotrectinib, can provide insights into the companys potential for future growth.
From a financial perspective, Zai Labs market capitalization is approximately $4.175 billion, and its return on equity (ROE) is -33.35%, indicating that the company is currently operating at a loss. However, this is not uncommon for biopharmaceutical companies with significant R&D investments. To assess the companys financial health, other KPIs such as cash reserves, operating expenses, and research and development expenditures should be monitored. A detailed analysis of these metrics can provide a more comprehensive understanding of Zai Labs financial situation and its ability to sustain its operations and invest in its pipeline.
ZLAB Stock Overview
| Market Cap in USD | 3,732m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-09-20 |
ZLAB Stock Ratings
| Growth Rating | 2.89% |
| Fundamental | 29.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 32.3% |
| Analyst Rating | 4.50 of 5 |
ZLAB Dividends
Currently no dividends paidZLAB Growth Ratios
| Growth Correlation 3m | -60.5% |
| Growth Correlation 12m | 71% |
| Growth Correlation 5y | -75.1% |
| CAGR 5y | -8.84% |
| CAGR/Max DD 3y | -0.12 |
| CAGR/Mean DD 3y | -0.21 |
| Sharpe Ratio 12m | 1.39 |
| Alpha | 0.00 |
| Beta | 0.981 |
| Volatility | 67.88% |
| Current Volume | 306.1k |
| Average Volume 20d | 657.2k |
| Stop Loss | 30.9 (-5.2%) |
| Signal | -0.42 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-212.5m TTM) > 0 and > 6% of Revenue (6% = 25.7m TTM) |
| FCFTA -0.24 (>2.0%) and ΔFCFTA -2.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 164.2% (prev 191.6%; Δ -27.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -175.3m > Net Income -212.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (109.2m) change vs 12m ago 11.89% (target <= -2.0% for YES) |
| Gross Margin 62.45% (prev 62.95%; Δ -0.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.77% (prev 32.68%; Δ 7.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -55.54 (EBITDA TTM -212.2m / Interest Expense TTM 4.10m) >= 6 (WARN >= 3) |
Altman Z'' -11.62
| (A) 0.60 = (Total Current Assets 1.03b - Total Current Liabilities 331.5m) / Total Assets 1.16b |
| (B) -2.18 = Retained Earnings (Balance) -2.54b / Total Assets 1.16b |
| warn (B) unusual magnitude: -2.18 — check mapping/units |
| (C) -0.21 = EBIT TTM -227.6m / Avg Total Assets 1.08b |
| (D) -6.70 = Book Value of Equity -2.50b / Total Liabilities 372.4m |
| Total Rating: -11.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.62
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -8.57% = -4.28 |
| 3. FCF Margin -64.61% = -7.50 |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda -1.07 = -2.50 |
| 6. ROIC - WACC (= -33.68)% = -12.50 |
| 7. RoE -27.32% = -2.50 |
| 8. Rev. Trend 95.33% = 7.15 |
| 9. EPS Trend 65.84% = 3.29 |
What is the price of ZLAB shares?
Over the past week, the price has changed by +14.72%, over one month by -8.71%, over three months by -12.47% and over the past year by +56.86%.
Is Zai Lab a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZLAB is around 28.89 USD . This means that ZLAB is currently overvalued and has a potential downside of -11.33%.
Is ZLAB a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZLAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.3 | 72.8% |
| Analysts Target Price | 56.3 | 72.8% |
| ValueRay Target Price | 32.4 | -0.6% |
Last update: 2025-09-05 05:09
ZLAB Fundamental Data Overview
CCE Cash And Equivalents = 732.2m USD (Cash And Short Term Investments, last quarter)
P/S = 8.7244
P/B = 4.3975
Beta = 1.033
Revenue TTM = 427.8m USD
EBIT TTM = -227.6m USD
EBITDA TTM = -212.2m USD
Long Term Debt = 40.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 185.7m USD (from shortTermDebt, last quarter)
Debt = 226.5m USD (Calculated: Short Term 185.7m + Long Term 40.9m)
Net Debt = -540.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.23b USD (3.73b + Debt 226.5m - CCE 732.2m)
Interest Coverage Ratio = -55.54 (Ebit TTM -227.6m / Interest Expense TTM 4.10m)
FCF Yield = -8.57% (FCF TTM -276.4m / Enterprise Value 3.23b)
FCF Margin = -64.61% (FCF TTM -276.4m / Revenue TTM 427.8m)
Net Margin = -49.68% (Net Income TTM -212.5m / Revenue TTM 427.8m)
Gross Margin = 62.45% ((Revenue TTM 427.8m - Cost of Revenue TTM 160.7m) / Revenue TTM)
Tobins Q-Ratio = -1.29 (set to none) (Enterprise Value 3.23b / Book Value Of Equity -2.50b)
Interest Expense / Debt = 0.56% (Interest Expense 1.26m / Debt 226.5m)
Taxrate = 21.0% (US default)
NOPAT = -227.6m (EBIT -227.6m, no tax applied on loss)
Current Ratio = 3.12 (Total Current Assets 1.03b / Total Current Liabilities 331.5m)
Debt / Equity = 0.29 (Debt 226.5m / last Quarter total Stockholder Equity 791.7m)
Debt / EBITDA = -1.07 (Net Debt -540.8m / EBITDA -212.2m)
Debt / FCF = -0.82 (Debt 226.5m / FCF TTM -276.4m)
Total Stockholder Equity = 777.8m (last 4 quarters mean)
RoA = -18.26% (Net Income -212.5m, Total Assets 1.16b )
RoE = -27.32% (Net Income TTM -212.5m / Total Stockholder Equity 777.8m)
RoCE = -27.80% (Ebit -227.6m / (Equity 777.8m + L.T.Debt 40.9m))
RoIC = -24.58% (NOPAT -227.6m / Invested Capital 925.9m)
WACC = 9.10% (E(3.73b)/V(3.96b) * Re(9.63%)) + (D(226.5m)/V(3.96b) * Rd(0.56%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 1.19%
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -276.4m)
EPS Correlation: 65.84 | EPS CAGR: 222.9% | SUE: 1.19 | # QB: 1
Revenue Correlation: 95.33 | Revenue CAGR: 26.56% | SUE: N/A | # QB: None
Additional Sources for ZLAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle